Cargando…

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del

Detalles Bibliográficos
Autores principales:	Beswick, Daniel M., Humphries, Stephen M., Balkissoon, Connor D., Strand, Matthew, E. Miller, Jessa, Khatiwada, Aastha, Vladar, Eszter K., Lynch, David A., Taylor‐Cousar, Jennifer L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373915/ https://www.ncbi.nlm.nih.gov/pubmed/34908251 http://dx.doi.org/10.1002/alr.22946

Ejemplares similares

Objective and patient‐based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy
por: Beswick, Daniel M., et al.
Publicado: (2022)

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes
por: Beswick, Daniel M., et al.
Publicado: (2022)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Decoding F508del Misfolding in Cystic Fibrosis
por: Wang, Xiaodong Robert, et al.
Publicado: (2014)

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
por: Zemanick, Edith T., et al.
Publicado: (2021)

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
por: Taylor-Cousar, Jennifer L., et al.
Publicado: (2019)

CFTR-F508 pigs provide new clues to cystic fibrosis
Publicado: (2011)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
por: Esposito, Speranza, et al.
Publicado: (2016)

ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis
por: Pankow, Sandra, et al.
Publicado: (2015)

P.F508del editing in cells from cystic fibrosis patients
por: Smirnikhina, Svetlana A., et al.
Publicado: (2020)

Management of pregnancy in cystic fibrosis
por: Montemayor, Kristina, et al.
Publicado: (2022)

Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice
por: Legssyer, Rachida, et al.
Publicado: (2006)

Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis,
por: Marson, Fernando Augusto de Lima, et al.
Publicado: (2013)

Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients
por: Melotti, Paola, et al.
Publicado: (2014)

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2018)

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
por: Taylor-Cousar, Jennifer L.
Publicado: (2020)

Expression of ΔF508 Cystic Fibrosis Transmembrane Regulator (CFTR) Decreases Membrane Sialylation
por: Dosanjh, Amrita, et al.
Publicado: (2009)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice
por: Dhooghe, Barbara, et al.
Publicado: (2015)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Ouabain Mimics Low Temperature Rescue of F508del-CFTR in Cystic Fibrosis Epithelial Cells
por: Zhang, Donglei, et al.
Publicado: (2012)

Calpain Inhibition Promotes the Rescue of F(508)del-CFTR in PBMC from Cystic Fibrosis Patients
por: Averna, Monica, et al.
Publicado: (2013)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
por: Kumar, Parameet, et al.
Publicado: (2021)

Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
por: Shteinberg, Michal, et al.
Publicado: (2020)

Case report: Three adult brothers with cystic fibrosis (delF508-delF508) maintain unusually preserved clinical profile in the absence of standard CF care
por: Bishop, Clark T.
Publicado: (2021)

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
por: Griese, Matthias, et al.
Publicado: (2021)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508‐CFTR for cystic fibrosis
por: Hodos, Rachel A., et al.
Publicado: (2021)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Potential of anti-inflammatory treatment for cystic fibrosis lung disease
por: Taylor-Cousar, Jennifer L, et al.
Publicado: (2010)

First report of the cystic fibrosis transmembrane conductance regulator mutation c.1521_1523delCTT (p. Phe508del) in two Qatari patients with cystic fibrosis
por: AbdulWahab, Atqah, et al.
Publicado: (2021)

Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation
por: Tomati, Valeria, et al.
Publicado: (2015)

Frequency of Genotype With ΔF508 Mutation in CFTR Gene Among Iranian Cystic Fibrosis Patients With Pancreatic Insufficiency
por: Khodadad, Ahmad, et al.
Publicado: (2015)

Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the Cftr-F508del mouse
por: Philp, Amber R., et al.
Publicado: (2018)

Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells
por: Sutanto, Erika N., et al.
Publicado: (2018)

Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR
por: Bose, Samuel J., et al.
Publicado: (2019)

Characterization of two rat models of cystic fibrosis—KO and F508del CFTR—Generated by Crispr‐Cas9
por: Dreano, Elise, et al.
Publicado: (2019)

Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue
por: Hodos, Rachel A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ssh74323b1c1o7nrsgup871r72